Comparative Pharmacology
Head-to-head clinical analysis: MOXEZA versus QUIXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOXEZA versus QUIXIN.
MOXEZA vs QUIXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.
Quixin (levofloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
400 mg orally once daily with or without food.
One to two drops in affected eye(s) every 2 hours while awake, up to 8 times daily for 7-14 days.
None Documented
None Documented
Terminal half-life: 12 hours; allows once-daily dosing
Terminal elimination half-life: 6–8 hours in adults with normal renal function; prolonged in renal impairment (up to 20 hours if CrCl <30 mL/min).
Renal: 70% unchanged; biliary/fecal: 20%; metabolized: 10%
Renal (approximately 70% unchanged in urine); biliary/fecal (~30%, partly as metabolites and unchanged drug).
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic